Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-101 in Celiac Disease
NCT04530123Phase 2Completed
- Sponsor
- Takeda
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of CNP-101 in celiac disease, sponsored by Takeda. Started Jun 2022; status: completed.
02
Drugs
CNP-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT04530123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04530123.